ClinicalTrials.gg
CompletedNCT02251275Updated Nov 27, 2019Results posted

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

A Phase 3 interventional study of Tolvaptan in Polycystic Kidney, Autosomal Dominant, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 210 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,803
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
Largest of 18
1,803 · median 91
Started
2014
with 1 other
Phase 3
8 of 18
none open now
Registered
11th of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one has the largest enrollment, is one of 2 that started in 2014, is one of 8 in phase 3, and was the 11th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).

Read the detailed description

This was a Phase 3b trial to evaluate and describe the long term safety of tolvaptan treatment in ADPKD participants with chronic kidney disease (CKD). Eligible participants could enroll into Trial 156-13-211 after completing the follow-up visit(s) of their previous trial (156-13-210, 156-08-271, 156-04-251, or 156-09-290). Renal function was assessed during screening by using historical laboratory values for serum creatinine levels to calculate the estimated glomerular filtration rate (eGFR).

03

Conditions studied

  • Polycystic Kidney, Autosomal Dominant

Keywords

  • ADPKD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants ≥ 18 years with confirmed diagnosis of ADPKD (during participation in prior tolvaptan trials) who have completed and transferred from the double-blind Trial 156-13-210 (12-month period including post treatment follow-up, regardless of whether this was on-treatment or off-treatment), or completed Trial 156-08-271 or a prior tolvaptan trial, or interrupted or discontinued treatment in a prior tolvaptan ADPKD trial other than Trial 156-13-210. Participants may be enrolled with the medical monitor approval, and additional close monitoring may be required at the beginning of the trial.
  • ≥ 20 milliliter (mL)/minute (min)/1.73 meter squared (m\^2) within 3 months prior to the baseline visit. Participants who have an eGFR ≤ 20 mL/min/1.73 m\^2 may be enrolled with medical monitor approval.

Exclusion criteria

Exclusion Criteria:

  • Need for chronic diuretic use
  • Hepatic impairment based on liver function abnormalities other than that expected for ADPKD with cystic liver disease
  • Women of who do not agree to practice 2 different methods of or remain abstinent during the trial and for 30 days after the last dose of medicinal product (IMP)
  • Women who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP.
  • Participants with to required trial assessments (contraindications to optional assessments, for example, magnetic resonance imaging [MRI] are not a limitation).
  • Participants who in the opinion of the investigator or the medical monitor, have a medical history or medical finding inconsistent with safety or trial compliance
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,803 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows: * Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability. * Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211. * Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.

    Drug: Tolvaptan

Interventions

  • Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later

    Also known as: OPC-41061

06

What researchers measure

Primary outcomes

  1. Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was as any untoward medical occurrence associated with the use of an investigational medicinal product (IMP), whether or not considered IMP related. A TEAE was an AE that started after trial drug treatment; or if the event was continuous from baseline and was serious, related to IMP, or resulted in death, discontinuation, interruption or reduction of trial therapy. A serious TEAE included any event that resulted in: death, life-threatening, persistent or significant incapacity, substantial disruption of ability to conduct normal life functions, required inpatient hospitalization, prolonged hospitalization, congenital anomaly/birth defect, or other medically significant events as per medical judgment, that jeopardized the participant and that required medical or surgical intervention. A severe TEAE was an inability to work or perform normal daily activity. A summary of serious and all other non-serious TEAEs, regardless of causality, is located in the AE section.

    Time frame: Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment(+ 7 days)

07

Results

Posted Nov 27, 2019

Participant flow

Eligible participants could enroll into Trial 156-13-211 after completing follow-up visit(s) of their previous trial (156-13-210, 156-08-271, 156-04-251, or 156-09-290).

Participant flow — Overall Study
MilestoneTolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)
Started50657071863
Received at least 1 dose of study drug50556971763
Completed43442362452
Not completed721479411
Withdrew: Adverse event23602800
Withdrew: Lost to follow-up56400
Withdrew: Physician decision19302601
Withdrew: Protocol deviation00100
Withdrew: Withdrawal by subject25513510

Outcome measures

PrimaryNumber Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was as any untoward medical occurrence associated with the use of an investigational medicinal product (IMP), whether or not considered IMP related. A TEAE was an AE that started after trial drug treatment; or if the event was continuous from baseline and was serious, related to IMP, or resulted in death, discontinuation, interruption or reduction of trial therapy. A serious TEAE included any event that resulted in: death, life-threatening, persistent or significant incapacity, substantial disruption of ability to conduct normal life functions, required inpatient hospitalization, prolonged hospitalization, congenital anomaly/birth defect, or other medically significant events as per medical judgment, that jeopardized the participant and that required medical or surgical intervention. A severe TEAE was an inability to work or perform normal daily activity. A summary of serious and all other non-serious TEAEs, regardless of causality, is located in the AE section.

Time frame:
Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment(+ 7 days)
Reported as:
Number · participants
Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
participantsTolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)
Participants with TEAEs47353164063
Participants with serious TEAEs879610312
Participants with severe TEAEs74788321
Discontinued due to TEAEs33653801
Deaths15300

Adverse events

Collected over Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment (+ 7 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan (From 156-13-210: Tolvaptan)1/505 (0.2%)87/505 (17.2%)469/505 (92.9%)
Tolvaptan (From 156-13-210: Placebo)5/569 (0.9%)96/569 (16.9%)525/569 (92.3%)
Tolvaptan (From 156-08-271: Tolvaptan)3/717 (0.4%)103/717 (14.4%)633/717 (88.3%)
Tolvaptan (From Other: Tolvaptan)0/6 (0%)1/6 (16.7%)6/6 (100%)
Tolvaptan (From Other: Placebo)0/3 (0%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 254
Most frequent serious events
EventTolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)
Ankle FractureInjury, poisoning and procedural complications1/5050/5691/7170/61/3
B-Cell Small Lymphocytic LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5050/5690/7170/61/3
Hypertensive CrisisVascular disorders0/5050/5691/7171/60/3
Renal Cyst InfectionInfections and infestations5/5058/5691/7170/60/3
Acute Kidney InjuryRenal and urinary disorders5/5058/5697/7170/60/3
Renal ImpairmentRenal and urinary disorders6/5052/5693/7170/60/3
End Stage Renal DiseaseRenal and urinary disorders3/5050/5698/7170/60/3
PneumoniaInfections and infestations4/5055/5690/7170/60/3
Alanine Aminotransferase IncreasedInvestigations3/5055/5691/7170/60/3
Blood Creatinine IncreasedInvestigations1/5055/5693/7170/60/3
Most frequent other events
Showing 10 of 67
Most frequent other events
EventTolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)
ThirstGeneral disorders139/505183/56991/7174/60/3
HaematuriaRenal and urinary disorders27/50552/56948/7170/62/3
Renal PainRenal and urinary disorders98/505110/569141/7173/62/3
HypertensionVascular disorders87/50577/569139/7174/61/3
Vulvovaginal Mycotic InfectionInfections and infestations3/2341/2906/3430/51/2
NocturiaRenal and urinary disorders77/505124/56958/7173/61/3
Vaginal HaemorrhageReproductive system and breast disorders0/2341/2903/3430/51/2
Motion SicknessEar and labyrinth disorders1/5051/5690/7170/61/3
Abdominal HerniaGastrointestinal disorders7/5051/5696/7170/61/3
ConstipationGastrointestinal disorders16/50528/56910/7170/61/3

Baseline characteristics

All participants who enrolled in the trial.

Age, Continuous
Age, Continuous(Years)Tolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)Total
Mean48.9 ± 8.148.6 ± 8.045.5 ± 7.841.2 ± 11.447.0 ± 2.647.4 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)Total
Female23429034352874
Male27228037511929
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)Total
Hispanic or Latino27254910102
Not Hispanic or Latino479545669531701
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tolvaptan (From 156-13-210: Tolvaptan)Tolvaptan (From 156-13-210: Placebo)Tolvaptan (From 156-08-271: Tolvaptan)Tolvaptan (From Other: Tolvaptan)Tolvaptan (From Other: Placebo)Total
American Indian or Alaska Native300003
Asian1616100042
Native Hawaiian or Other Pacific Islander102003
Black or African American192360048
White461525694631689
More than one race000000
Unknown or Not Reported6660018
08

Study locations

210 sites
  • Birmingham, Alabama 35233, United States
  • Huntsville, Alabama 35805, United States
  • Mobile, Alabama 36617, United States
  • Phoenix, Arizona 85381, United States
  • Tempe, Arizona 85284, United States
  • Tucson, Arizona 85745, United States
  • La Jolla, California 92037, United States
  • Los Angeles, California 90022, United States
  • Los Angeles, California 90095, United States
  • San Francisco, California 94143, United States
  • Stanford, California 94305, United States
  • Aurora, Colorado 80045, United States
  • Denver, Colorado 80204, United States
  • Denver, Colorado 80210, United States
  • New Haven, Connecticut 06520, United States
  • Hudson, Florida 34667, United States
  • Jacksonville, Florida 32216, United States
  • Miami, Florida 33150, United States
  • Ocala, Florida 34471, United States
  • Port Charlotte, Florida 33952, United States
  • Tampa, Florida 33614, United States
  • Atlanta, Georgia 30322, United States
  • Augusta, Georgia 30909, United States
  • Meridian, Idaho 83642, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60637, United States
  • Kansas City, Kansas 66160, United States
  • Wichita, Kansas 67214, United States
  • Baton Rouge, Louisiana 70808, United States
  • Baltimore, Maryland 21201, United States
  • Baltimore, Maryland 21224, United States
  • Greenbelt, Maryland 20770, United States
  • Rockville, Maryland 20850, United States
  • Boston, Massachusetts 02111, United States
  • Springfield, Massachusetts 01107, United States
  • Detroit, Michigan 48202, United States
  • Grand Rapids, Michigan 49506, United States
  • Kalamazoo, Michigan 49007, United States
  • Pontiac, Michigan 48341, United States
  • Roseville, Michigan 48066, United States
  • Rochester, Minnesota 55905, United States
  • Saint Louis, Missouri 63110, United States
  • Las Vegas, Nevada 89106, United States
  • Reno, Nevada 89511, United States
  • Eatontown, New Jersey 07724, United States
  • Voorhees, New Jersey 08043, United States
  • Buffalo, New York 14219, United States
  • Laurelton, New York 11413, United States
  • Mineola, New York 11501, United States
  • New York, New York 10021, United States
  • New York, New York 10032, United States
  • Asheville, North Carolina 28801, United States
  • Chapel Hill, North Carolina 27599, United States
  • Charlotte, North Carolina 28207, United States
  • Winston-Salem, North Carolina 27103, United States
  • Fargo, North Dakota 58102, United States
  • Akron, Ohio 44302, United States
  • Cincinnati, Ohio 45206, United States
  • Cincinnati, Ohio 45229, United States
  • Cleveland, Ohio 44106, United States
  • Columbus, Ohio 43210, United States
  • Portland, Oregon 97210, United States
  • Bethlehem, Pennsylvania 18017, United States
  • Doylestown, Pennsylvania 18901, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Charleston, South Carolina 29425, United States
  • Columbia, South Carolina 29203, United States
  • Orangeburg, South Carolina 29118, United States
  • Knoxville, Tennessee 37923, United States
  • Nashville, Tennessee 37205, United States
  • Nashville, Tennessee 37232, United States
  • Arlington, Texas 76015, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77030, United States
  • McAllen, Texas 78503, United States
  • Burlington, Vermont 05401, United States
  • Arlington, Virginia 22207, United States
  • Charlottesville, Virginia 22908, United States
  • Norfolk, Virginia 23507, United States
  • Wenatchee, Washington 98801, United States
  • Morgantown, West Virginia 26506, United States
  • Ciudad Autonoma de Buenos Aires, Buenos Aires C1093AAS, Argentina
  • Ciudad Autonoma de Buenos Aires, Buenos Aires C1425APQ, Argentina
  • Ciudad Autonoma de Buenos Aires, Buenos Aires C1429BWN, Argentina
  • Ciudad Autonoma de Buenos Aires, Buenos Aires C1431FWO, Argentina
  • Junin, Buenos Aires 6000, Argentina
  • Pergamino, Buenos Aires B2700CPM, Argentina
  • Pilar, Buenos Aires B1629ODT, Argentina
  • Córdoba, X5000JHQ, Argentina
  • Córdoba, X5016KEH, Argentina
  • Córdoba, X5166BPW, Argentina
  • Camperdown, New South Wales 2050, Australia
  • New Lambton Heights, New South Wales 2305, Australia
  • St Leonards, New South Wales 2065, Australia
  • Westmead, New South Wales 2145, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Adelaide, South Australia 5000, Australia
  • Launceston, Tasmania 7250, Australia
  • Parkville, Victoria 3050, Australia
  • Reservoir, Victoria 3073, Australia

Showing the first 100 of 210 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):48-58. doi: 10.2215/CJN.10250620. Epub 2020 Dec 29. PubMed 33376102 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Nov 2018, 48 months.

Results were first posted in Nov 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Sep 29, 2014
StartActual
Oct 17, 2014
Primary completionActual
Nov 9, 2018
CompletionActual
Nov 9, 2018
Results first posted
Nov 27, 2019
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02251275
Responsible party
Sponsor
First posted
Sep 29, 2014
Start date
Oct 17, 2014
Primary completion
Nov 9, 2018
Completion
Nov 9, 2018
Results posted
Nov 27, 2019
Last update
Nov 27, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion